secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2024-07-10T23:59:59+00:00
Accession:  0001193125-24-177000
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.01
LLM model:  deepseek-v4-flash:cloud@v2

Amylyx completes acquisition of Avexitide from Eiger for $35.1M
---------------------------------------------------------------

- Acquired Avexitide from Eiger BioPharmaceuticals for $35.1 million plus cure costs and assumed liabilities.
- Sale approved by U.S. Bankruptcy Court for Northern District of Texas on June 26, 2024; closed July 9, 2024.
- Amylyx will handle development, manufacture, and commercialization of Avexitide post-closing.
- Transaction follows Asset Purchase Agreement dated June 21, 2024, as previously disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000119312524177000/0001193125-24-177000-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000119312524177000/d853448d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-177000

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer